Description
Small molecule generics (tablets, capsules, oral liquids, and injectables) form the backbone of treatment across communicable and non-communicable diseases, supporting first-line therapies for infections, cardiovascular conditions, and chronic diseases. The total small molecule FDF market in Ethiopia is ~$345 Mn, with demand heavily concentrated in oral solids (~70–80% of value), followed by injectables and a smaller share of oral liquids.
